1. Clinical Overview
Cerebroprotein Hydrolysate is a sterile, pyrogen-free, low molecular weight preparation derived from porcine brain tissue through enzymatic hydrolysis. It contains biologically active peptides, amino acids, and neurotrophic factors. In the Indian context, it is widely prescribed as a neuroprotective and neurotrophic agent for various neurological conditions, primarily to support cognitive recovery and neuronal repair. It is considered a neurometabolic cerebroprotector.
| Onset | Duration | Bioavailability |
|---|---|---|
| The onset of therapeutic effect is gradual, typically observed after 2-4 weeks of continuous therapy. | The duration of action is not precisely defined but is believed to be sustained over several hours post-administration, with cumulative benefits seen over weeks to months of treatment. | Data on absolute bioavailability in humans is limited. As a mixture of peptides and amino acids, it is presumed to have variable absorption from the intramuscular route. Direct CNS bioavailability after systemic administration is a subject of research. |
2. Mechanism of Action
Exerts its effects through a multimodal mechanism. It provides a source of peptides and amino acids that may act as precursors for neurotransmitter synthesis. It is believed to mimic endogenous neurotrophic factors, promoting neuronal survival, synaptogenesis, and repair. It may enhance cerebral glucose uptake and utilization, improve microcirculation, and stabilize neuronal membranes.
3. Indications & Uses
- Adjunctive therapy in post-stroke recovery and rehabilitation
- Traumatic brain injury (sequelae management)
- Cognitive impairment associated with aging (e.g., mild cognitive impairment)
- Peripheral neuropathy (as an adjunct)
4. Dosage & Administration
Adult Dosage: 30mg once daily, administered by deep intramuscular (IM) injection. The standard course is 10-20 injections, which may be repeated after a break of 2-4 weeks based on clinical assessment.
Administration: For IM use only. Do not administer intravenously. Use a deep intramuscular injection, preferably in the gluteal region. The powder must be reconstituted strictly with the provided solvent (usually Water for Injection). Use immediately after reconstitution. Do not mix with other injections in the same syringe.
5. Side Effects
Common side effects may include:
- Pain, redness, or induration at the injection site
- Mild fever (pyrogenic reaction)
- Headache
- Dizziness
6. Drug Interactions
| Drug | Effect | Severity |
|---|---|---|
| Antiepileptic Drugs (e.g., Phenytoin, Valproate) | Theoretical risk of reduced seizure threshold; monitor for seizure activity. | Moderate |
| Other Nootropics/Cerebral Activators (e.g., Piracetam, Citicoline) | Additive pharmacological effect; combination is common in practice but may increase risk of side effects like agitation. | Mild |
| Anticoagulants/Antiplatelets (e.g., Warfarin, Aspirin) | No direct pharmacokinetic interaction known. Use with caution as both may be used in stroke patients. | Mild |
7. Patient Counselling
- Do complete the prescribed course of injections for optimal benefit.
- Do report any pain or swelling at the injection site.
- Do inform your doctor about all other medications you are taking.
- Do not self-administer; get injections from a trained healthcare professional.
- Do not use if the solution is discolored or contains particles.
8. Toxicology & Storage
Overdose: No specific reports of acute overdose in humans. Symptoms may be an exaggeration of side effects: severe agitation, fever, pronounced injection site reaction, and potentially seizures.
Storage: Store the vial (powder) and solvent below 25°C. Protect from light. Do not freeze. After reconstitution, the solution should be used immediately and must not be stored. Keep out of reach of children.